Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

Gray, or gray market medications, are nothing new, and GLP-1s — the class of weight loss wonder drug that includes ...

Net loss for the three months ended March 31, 2025, totaled $11.1 million, with non-cash share-based compensation expense of ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Adverse reactions to weight-loss jabs are set to soar by more than 350% in a single year, according to the latest data.

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals ...

Medicaid enrollees with type 2 diabetes face restricted access to newer classes of first-line medications, especially in ...

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...